Profile data is unavailable for this security.
About the company
CervoMed Inc. is a clinical-stage biotechnology company focused on developing treatments for age-related neurologic disorders. It is focused on the development of its lead drug candidate, neflamapimod, an investigational, orally administered, small molecule brain penetrant that inhibits p38a in the neurons (nerve cells) within the brains of people with neurodegenerative diseases. Its neflamapimod is in clinical development as a disease-modifying treatment for neurodegenerative diseases, such as dementia with Lewy Bodies and early Alzheimer’s disease. In addition, pre-clinical data supports the potential role of neflamapimod in recovery after stroke. Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in dementia with Lewy bodies (DLB) and certain other neurological disorders. It is being evaluated in its ongoing RewinD-LB Trial, a Phase 2b study in patients with DLB.
- Revenue in USD (TTM)7.14m
- Net income in USD-2.17m
- Incorporated2015
- Employees8.00
- LocationCervoMed Inc20 Park Plaza, Suite 424BOSTON 02116United StatesUSA
- Phone+1 (617) 744-4400
- Fax+1 (434) 220-0722
- Websitehttps://cervomed.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Outlook Therapeutics Inc | 0.00 | -51.50m | 189.54m | 24.00 | -- | -- | -- | -- | -3.99 | -3.99 | 0.00 | -1.87 | 0.00 | -- | -- | 0.00 | -122.07 | -214.69 | -441.62 | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -- | 3.00 | -- | -- | -- | 10.70 | -- | -- | -- |
| Rigel Pharmaceuticals Inc | 116.88m | -25.09m | 191.19m | 147.00 | -- | -- | -- | 1.64 | -0.1444 | -0.1444 | 0.6717 | -0.1638 | 0.9295 | 0.9713 | 3.30 | 795,115.60 | -19.95 | -28.82 | -37.72 | -47.26 | 93.92 | 97.88 | -21.47 | -35.76 | 1.76 | -4.45 | 1.93 | -- | -2.79 | 21.30 | 57.16 | -- | 68.45 | -- |
| Atossa Therapeutics Inc | 0.00 | -30.09m | 191.72m | 10.00 | -- | 2.11 | -- | -- | -0.2386 | -0.2386 | 0.00 | 0.7264 | 0.00 | -- | -- | 0.00 | -27.39 | -29.97 | -28.80 | -32.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -11.62 | -- | -33.90 | -- |
| Generation Bio Co | 5.90m | -126.61m | 193.48m | 174.00 | -- | 0.9485 | -- | 32.77 | -1.97 | -1.97 | 0.0916 | 3.07 | 0.0157 | -- | 2.71 | 33,931.04 | -33.72 | -36.96 | -36.60 | -39.21 | -- | -- | -2,144.51 | -8,879.44 | -- | -- | 0.00 | -- | -- | 177.31 | 7.34 | -- | 19.61 | -- |
| Acumen Pharmaceuticals Inc | 0.00 | -52.37m | 195.26m | 51.00 | -- | 0.705 | -- | -- | -1.08 | -1.08 | 0.00 | 4.61 | 0.00 | -- | -- | 0.00 | -20.67 | -- | -21.56 | -- | -- | -- | -- | -- | -- | -- | 0.103 | -- | -- | -- | -22.20 | -- | -- | -- |
| Lifecore Biomedical Inc | 103.27m | -64.24m | 196.72m | 459.00 | -- | -- | -- | 1.90 | -2.12 | -3.29 | 3.43 | 1.16 | 0.391 | 1.96 | 3.07 | 224,986.90 | -24.32 | -5.67 | -41.13 | -8.07 | 27.10 | 21.91 | -62.20 | -11.90 | 1.35 | -1.05 | 0.7495 | -- | -7.19 | -27.74 | -315.07 | -- | -8.55 | -- |
| Omeros Corp | 0.00 | -174.92m | 197.01m | 198.00 | -- | -- | -- | -- | -2.79 | -1.88 | 0.00 | -0.4087 | 0.00 | -- | -- | 0.00 | -36.09 | -55.51 | -44.88 | -70.10 | -- | -- | -- | -- | -- | -5.33 | 1.08 | -- | -- | -- | 3.91 | -- | -5.56 | -- |
| Trevi Therapeutics Inc | 0.00 | -29.07m | 197.23m | 25.00 | -- | 2.37 | -- | -- | -0.2934 | -0.2934 | 0.00 | 1.21 | 0.00 | -- | -- | 0.00 | -27.37 | -47.39 | -30.09 | -54.41 | -- | -- | -- | -- | -- | -- | 0.0019 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| CervoMed Inc | 7.14m | -2.17m | 199.49m | 8.00 | -- | 18.59 | -- | 27.92 | -0.6282 | -0.6282 | 2.07 | 1.30 | 0.4382 | -- | -- | 893,108.80 | -13.32 | -53.67 | -15.74 | -58.89 | -- | -- | -30.40 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Zevra Therapeutics Inc | 27.46m | -46.05m | 199.76m | 65.00 | -- | 3.09 | -- | 7.27 | -1.29 | -1.29 | 0.7746 | 1.49 | 0.1909 | -- | 2.14 | 422,476.90 | -32.02 | -32.11 | -45.61 | -39.89 | 45.22 | -- | -167.69 | -128.42 | -- | -- | 0.4058 | -- | 170.26 | -- | -72.00 | -- | 69.75 | -- |
| Telomir Pharmaceuticals Inc | 0.00 | -13.07m | 202.09m | 1.00 | -- | 56.79 | -- | -- | -0.48 | -0.48 | 0.00 | 0.1202 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2.40 | 0.0285 | -- | -- | -- | -1,430.39 | -- | -- | -- |
| Adverum Biotechnologies Inc | 3.60m | -117.17m | 203.19m | 121.00 | -- | 1.19 | -- | 56.44 | -11.62 | -11.62 | 0.3571 | 8.23 | 0.015 | -- | -- | 29,752.07 | -48.68 | -36.39 | -55.24 | -39.04 | -- | -- | -3,254.58 | -5,279.60 | -- | -- | 0.00 | -- | -- | 17.43 | 24.18 | -- | -0.0247 | -- |
| Design Therapeutics Inc | 0.00 | -66.86m | 204.51m | 58.00 | -- | 0.7362 | -- | -- | -1.19 | -1.19 | 0.00 | 4.92 | 0.00 | -- | -- | 0.00 | -21.20 | -- | -21.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -121.83m | 204.85m | 128.00 | -- | 0.8639 | -- | -- | -2.05 | -2.05 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -48.91 | -47.21 | -53.60 | -51.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Conduit Pharmaceuticals Inc | -100.00bn | -100.00bn | 208.20m | -- | -- | -- | -- | -- | -- | -- | -- | -0.0149 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Data as of May 02 2024. Currency figures normalised to CervoMed Inc's reporting currency: US Dollar USD
19.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| RA Capital Management LPas of 01 Apr 2024 | 825.37k | 13.38% |
| Adage Capital Management LPas of 31 Dec 2023 | 199.35k | 3.23% |
| CWM LLCas of 31 Mar 2024 | 59.09k | 0.96% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 29.03k | 0.47% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 21.90k | 0.36% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 19.32k | 0.31% |
| Geode Capital Management LLCas of 31 Dec 2023 | 15.71k | 0.26% |
| Hoey Investments, Inc.as of 31 Dec 2023 | 1.08k | 0.02% |
| Tower Research Capital LLCas of 31 Dec 2023 | 725.00 | 0.01% |
| Vanguard Global Advisers LLCas of 31 Dec 2023 | 598.00 | 0.01% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
